Preview complete
The prescreener preview is complete. You may now close the preview.
A study to evaluate the impact of cariprazine (1.5mg) on cocaine use in OUD-CocUD patients on buprenorphine-naloxone.
Recruiting
18-65 years
All
Phase
2
48 participants needed
1 Location
Brief description of study
The research study is being conducted to understand whether the medication, cariprazine, affects drug use, and brain and behavioral responses in people with opioid and cocaine use disorder already being treated with the medication buprenorphine-naloxone (brand names: Suboxone, Zubsolv, Bunavail). Cariprazine (VRAYLAR ) is FDA-approved for the treatment of certain mood and thought disorders, but is considered an investigational medication in this study as it is not FDA-approved for the treatment of opioid and cocaine use disorder
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: opioid and cocaine use disorder
-
Age: Between 18 Years - 65 Years
-
Gender: All
Males and Females, Aged 18-65 years old, have been on a stable dose of BUP-NX for at least one week, and plan to continue taking BUP-NX for at least 12 weeks
Updated on
01 Aug 2024.
Study ID: 849150
Pre-Screener
